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ORIGINAL ARTICLE
Patient-reported outcomes in topical field treatment of actinic keratosis in
Swedish and Danish patients
Hanna Norrlida, Jenny M. Norlina, Heidi Holmstrupb, Irena Malmbergb, Karin Sartoriusc, Henrik Thormannd,
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Hospital, Roskilde, Denmark; fDepartment of Health Sciences, University of Copenhagen, Copenhagen, Denmark
ABSTRACT
Topical treatments in dermatology can be long, complex and lead to nonadherence and nonpersistence
to prescribed treatment. Clinical efficacy observed in randomized clinical trials (RCT) may therefore be
reduced in real-world clinical practice. The objective of this study was to analyze patient-reported treat-
ment adherence, treatment satisfaction and health-related quality of life (HRQoL) with topical treatments
of actinic keratosis (AK) in routine clinical practice in Denmark and Sweden. Adult patients prescribed
field-directed topical AK treatments with diclofenac gel, imiquimod or ingenol mebutate per routine clin-
ical practice were eligible for the observational RAPID-ACT study. Data were collected through physician
and patient questionnaires that included validated instruments to measure treatment satisfaction (TSQM-
9), treatment adherence (MMAS) and HRQoL (EQ-5D-5L, EQ-VAS, AKQoL). In total, 446 patients from
Denmark and Sweden were included. Ingenol mebutate patients reported a higher satisfaction with treat-
ment effectiveness compared to patients treated with diclofenac (p¼ .006) while no other differences in
treatment satisfaction could be determined. Treatment adherence was generally high, but higher for
ingenol mebutate compared to both diclofenac (p< .001) and imiquimod (p¼ .007), possibly due to
shorter treatment duration. No differences in improved HRQoL were found. More research is needed
about the link between treatment adherence and real-world effectiveness.
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Actinic keratosis (AK) is a common skin condition caused by
cumulative sun exposure (1). Diagnosis is based on histology of
clinically suspect lesions, but various imaging technologies are
being tested as diagnostic aids (2–6). Some AK lesions spontan-
eously regress (7), while a minority may progress to squamous cell
carcinoma (SCC) (8–10). Single lesions most often appear as a con-
sequence of field cancerization in a generally sun exposed area of
the skin (2). AK prevalence has been estimated to between 1.4%
and 25% of the population (11–14) and known risk factors are
age, cumulative sun exposure, Fitzpatrick skin type and previous
AK diagnosis (15,16). Current guidelines mostly recommend active
treatment of AK, both to reduce symptoms and to lower the risk
of developing SCC (17–19), although Danish guidelines accept “no
treatment” as a valid treatment option (20).
AK has shown to impair health-related quality of life (HRQoL)
(21,22). AK lesions are often red and scaly and may cause itching
and bleeding. As AK lesions are caused by cumulative sun expos-
ure they often develop in visible skin areas (e.g. face, scalp and
hands). Patients also fear that their AK lesion may develop into
NMSC (23). These factors may influence a person’s HRQoL. Yet,
knowledge about the impact of AK and AK treatments on
patients’ HRQoL is limited (22,24–26).
There are many treatment options available for AK and in
addition to targeted therapy such as cryotherapy, multiple field-
directed treatments are listed in the Danish and Swedish treatment
guidelines (17,20). Targeted therapy targets only single visible AK
lesions, and recurrence rates are therefore high (27,28). Field-
directed treatments, on the other hand, target both visible and
nonvisible multiple lesions and are therefore often used for areas
of field cancerization (27). Field-directed treatments include photo-
dynamic therapy (PDT) and topical treatments applied to the skin
by the patient. Treatment regimens of topical AK treatments may
last from 2 to 90 days with varying dosing complexity (29).
All AK therapies may cause local skin reactions (LSRs), such as
blistering, inflammation, erythema, ulceration, burning and pain
(27). LSRs are common and often last throughout the treatment
duration and persist 2 to 4weeks after treatment completion (30).
In some cases, patients need treatment-free periods due to severe
LSRs.
Topical treatments in dermatology are often challenging due
to prolonged and complex treatment regimens and can often
lead to nonadherence and nonpersistence to prescribed treat-
ment (31–33). Clinical efficacy observed in randomized clinical
trials (RCT) may therefore be reduced in real-world clinical prac-
tice (32,34). While RCTs assess the safety and efficacy of a
drug, whether it can work under ideal condition; observational
studies are used to assess the effectiveness of drugs, that is,
whether it works in a heterogenous population in clinical prac-
tice. As treatment adherence may influence the effectiveness of
a drug, knowledge about adherence of drugs is important to
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inform decisions on treatment prioritizations and clinical
guidelines.
In 2014 and 2015, an observational study of topical field treat-
ment of AK, the Real-Life Topical Field Treatment of Actinic
Keratosis (RAPID-ACT, NCT02362152), was conducted in Sweden,
Denmark, United Kingdom, the Netherlands and Canada. The pre-
sent paper studies Danish and Swedish data from the RAPID-ACT.
The objective of this study was to analyze patient-reported treat-
ment adherence, treatment satisfaction and HRQoL in patients
with topical treatment for AK in routine clinical practice in
Denmark and Sweden using a subset of the RAPID-ACT data.
Materials and methods
Study design
Adult patients diagnosed with AK and prescribed field-directed
topical treatments with diclofenac gel, imiquimod 3.75% or 5% or
ingenol mebutate 150 lg/g or 500lg/g by their physician,
were eligible for the RAPID-ACT study in Denmark and Sweden
(Table 1). In the observational RAPID-ACT trial, each physician
selected the treatment per routine clinical practice.
Physicians reported baseline patient characteristics, while
patients reported outcomes in terms of treatment satisfaction,
adherence, HRQoL and resource utilization (the latter is not ana-
lyzed in this paper). Patients filled out questionnaires at the base-
line visit and were given a follow-up questionnaire to fill out
3weeks (21 days) after completed treatment. The study did not
include any protocol-driven follow-up visits.
The RAPID-ACT trial received ethical approval from the Ethical
Board in Stockholm, Sweden, in December 2014 (Dnr 2014/
2026–31/4). Ethical approval is not required for non-interventional
studies in Denmark. Patients were enrolled at 18 sites in Denmark
and 20 sites in Sweden.
Study population
This paper includes the Danish and Swedish population of the
RAPID-ACT trial. The Danish and Swedish populations can be
assumed to have similar geographical, demographical and genetic
conditions and could therefore be combined in a pooled analysis
in terms of treatment outcomes. Patients who did not state the
type of AK treatment and patients with AK lesions on more than
one body part were excluded to enable analysis by treatment and
by body part.
Outcomes measures
The RAPID-ACT questionnaires included a set of validated instru-
ments that measure treatment satisfaction, treatment adherence
and HRQoL. The Treatment Satisfaction Questionnaire for
Medication (TSQM)-9 includes nine questions that assess patients’
treatment satisfaction by providing score on three scales; effect-
iveness, convenience and global satisfaction (35). The scores of
each scale range from 0 to 100, where a higher score indicates a
greater satisfaction. The TSQM questionnaire is widely used in a
variety of disease areas (36,37).
The Morisky Medication Adherence Scale (MMAS) is a four-item
patient questionnaire that estimates treatment adherence (38,39).
Questions are scored as “Yes”¼0 and “No”¼1. The items are
summed to give a range of scores from 0 to 4, where 0 is inter-
preted as “High Adherence,” 1–2 as “Medium Adherence” and 3–4
as “Low Adherence.”
The EuroQol-5 dimension (EQ-5D) is a generic standardized
instrument to measure HRQoL (40). The instrument includes five
dimensions; mobility, self-care, usual activities, pain/discomfort
and anxiety/depression. The EQ-5D-5L version includes five
response levels; no problems, slight problems, moderate prob-
lems, severe problems, unable to/extreme problems. An utility
weight value set for England from 2016 (41) was used to calculate
the EQ-5D-5L index scores. The EuroQol Visual Analogue Scale
(EQ-VAS) is a subsection of the EQ-5D instrument that asks
respondents to indicate their current health state on a scale from
0 (worst imaginable health state) to 100 (best imaginable health
state). The result of primary interest, with both the EQ-5D-5L and
the EQ-VAS instruments, is the difference in HRQoL between base-
line and follow-up, that is, whether the treatment results in
improved HRQoL. Therefore, patients who did not complete the
follow-up questionnaire were excluded from these analyses.
Recently, a disease specific HRQoL index called the Actinic
Keratosis Quality of Life Questionnaire (AKQoL) was developed (24).
This questionnaire reflects how sun-damaged skin affects HRQoL
by focusing on psychological aspects. The AKQoL includes nine
questions regarding personal daily life, personal view of quality of
life, social life, emotional life and control of life (24). Each question
is scored on a 4-point scale; “a lot/all the time”¼3, “quite a lot/
often”¼2, “some/sometimes”¼1, “rarely/not at all”¼0. By summing
the score of each question the total score range from 0 to 27,
where a higher score implies a larger HRQoL impairment (24).
Trial subjects were also asked whether they experienced LSRs
or not.
Statistical analyses
t-Tests were used to test differences between two large samples
while Kruskal–Wallis tests were used to test differences in groups
(presented in tables). When differences were found within a
group, Mann–Whitney/Wilcoxon tests – suitable for tests of two
smaller samples – were used to test differences between individ-
ual treatments (presented in text upon statistically significant
differences).
Since strength-specific sample sizes were small, analyses were
conducted by pooling treatment strengths. Mann–Whitney/
Wilcoxon tests were then used in a subgroup analysis to test dif-
ferences between treatments strengths of imiquimod (3.75% vs.
5%) and ingenol mebutate (150 lg/g vs. 500lg/g) in TSQM-9,
Table 1. Included topical treatments for actinic keratosis.
Drug Strength Indication in label Treatment regimen
Diclofenac gel (SolarazeVR ) 3% AK lesions 2/day for 60–90 consecutive days
Imiquimod cream (ZyclaraVR ) 3.75% AK lesions on face/scalp 1/day for 2 weeks – 2 weeks without
treatment –1/day for 2 week
Imiquimod cream (AldaraVR ) 5% AK lesions on face/scalp 3/week for 4 weeks – 4 weeks without
treatment – If the lesions are not fully
healed: 3/week for another 4 week
Ingenol mebutate gel (PicatoVR ) 150lg/g AK lesions on face/scalp 1/day for 3 consecutive days
Ingenol mebutate gel (PicatoV
R
) 500lg/g AK lesions on trunk/extremities 1/day for 2 consecutive days
All treatment details, for all treatments, were gathered from (29).
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MMAS, AKQoL, EQ-5D-5L, EQ-VAS and frequency of LSR. A signifi-
cance level of 5% (p.05) was applied for statistical significance in
all cases.
Results
A total of 446 patients were included in the analysis. Patient and
lesion characteristics are presented in Table 2.
Treatment satisfaction and adherence
Treatment satisfaction is presented in Figure 1 and Table 3.
Ingenol mebutate patients reported a higher satisfaction with
treatment effectiveness compared to patients treated with diclofe-
nac (p¼ .006) and the difference between diclofenac and imiqui-
mod was borderline significant (p¼ .061), while the difference
between imiquimod and ingenol mebutate was not statistically
significant (p¼ .285).
Treatment adherence was generally high (Table 3). Ingenol
mebutate patients reported better treatment adherence compared
to both diclofenac (p< .001) and imiquimod patients (p¼ .007).
Health-related quality of life
AKQoL was measured at baseline. Diclofenac patients reported a
higher HRQoL impairment in terms of AKQoL compared to
patients treated with imiquimod (p¼ .048) or ingenol mebutate
(p¼ .017). No statistically significant differences were found
between imiquimod and ingenol mebutate at baseline (p¼ .667).
The EQ-5D-5L and the EQ-VAS instruments showed no statistically
significant differences in HRQoL improvement from baseline to
follow-up between treatment groups (Table 3).
Local skin reactions
LSRs were less common in patients treated with diclofenac (42%)
compared to those treated with imiquimod (79%; p< .001) or
ingenol mebutate (89%; p< .001) and less common with imiqui-
mod compared to ingenol mebutate (p¼ .015).
Subgroup analysis
In total, 45 patients were treated with imiquimod 3.75%, 102
patients with imiquimod 5%, 241 with ingenol mebutate 150lg/g
and 18 were treated with ingenol mebutate 500lg/g. No statistic-
ally significant differences were found between treatment strengths
for either imiquimod or ingenol mebutate (data not shown).
Discussion
In this real-world study of Danish and Swedish AK patients,
ingenol mebutate-treated patients reported a higher satisfaction
Table 2. Patient and lesion characteristics.
Diclofenac Imiquimod Ingenol Mebutate Total
Background variable n % n % n % n % p value
n 40 9% 147 33% 259 58% 446 100% –
Nationality, Danish 40 100% 96 65% 107 41% 243 47% <.001
Age, mean (SD)a 70.8 (7.8) 70.8 (8.1) 69.1 (9.6) 69.9 (9.0) .326
Gender, female 9 23% 57 39% 130 50% 196 44% .001
Previous AK diagnosis 31 78% 112 76% 190 73% 333 75% .747
Previously treated AKb 32 80% 108 73% 192 74% 332 74% .237
Previous skin cancer
SCC 1 3% 14 10% 14 5% 29 7% .152
BCC 10 25% 57 39% 87 34% 154 35% .238
Melanoma – – 9 6% 13 5% 22 5% .284
Comorbidityc 21 53% 75 51% 159 61% 255 57% .105
Fitzpatrick skin typed .748
I 5 13% 28 19% 45 17% 78 17%
II 32 80% 99 67% 172 66% 303 68%
III 3 8% 19 13% 40 15% 62 14%
IV – – 1 1% 2 1% 3 1%
Body part of current AK lesion .984e
Face 17 43% 103 70% 194 75% 314 70%
Scalp 20 50% 32 22% 45 17% 97 22%
Trunk 2 5% 8 5% 9 3% 19 4%
Extremities 1 3% 4 3% 11 4% 16 4%
Mean number of lesions, (SD) 20.0 (13.7) 9.0 (7.9) 8.1 (5.9) 9.4 (8.2) <.001
Mean lesion size, cm2 (SD) 54.9 (72.2) 24.8 (39.9) 18.6 (14.8) 23.8 (34.6) <.001
Field previously treated for AK 25 64% 87 60% 144 56% 256 57% .562
Number of treatment cycles prescribedf <.001
1 30 75% 63 43% 247 95% 340 76%
2 7 18% 83 56% 4 2% 94 21%
3 – – – – 7 3% 7 2%
4, or more 3 8% 1 1% 1 0% 5 1%
SD: standard deviation.
aAge was patient-reported. Age information was missing for 93 ingenol mebutate patients, 34 imiquimod 5% patients, 7 imiquimod 3.75% patients and 15 diclofe-
nac patients.
bThere were three missing values in the diclofenac group.
cComorbidities include heart/circulation problems, depression, anxiety, chest/respiratory problems, gut/bowel problems, joint problems, diabetes, cancer (not includ-
ing skin cancer), skin disorders and immunosuppressed diseases.
dThere are six Fitzpatrick skin types (I–VI). Only four of these were represented among the Danish and Swedish AK-patients in the RAPID-ACT study; Type I – always
burn, never tans; Type II – usually burn, then tans; Type III – may burn, tans well; Type IV – rarely burns, tans well.
eTest refers to proportion with lesions on face/scalp versus trunk/extremities.
fMissing values and 0 cycles were interpreted as one treatment cycle, as that was an inclusion criteria of the RAPID-ACT study.
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with treatment effectiveness compared to patients treated with
diclofenac. No other differences in treatment satisfaction were
found. Self-reported treatment adherence was high in all groups,
the highest among ingenol mebutate patients. No differences
could be detected in HRQoL improvement from baseline and after
treatment with either EQ-5D-5L or EQ-VAS. LSRs were most com-
mon with ingenol mebutate followed by imiquimod, and least
common with diclofenac.
The strength of observational studies is that they provide add-
itional information that complement RCTs, as it captures adher-
ence and patient perceived effectiveness in a real-world setting.
The three treatment populations were similar in terms of patient
and background characteristics, except for the fraction of female
patients and national differences in choice of treatment, which is
subject to guideline differences. Product label differences may
explain treatment groups differences in number of lesions, aver-
age lesion size and number of prescribed treatment cycles, that is,
diclofenac has a general indication for “AK lesions,” ingenol mebu-
tate and imiquimod 5% are explicitly indicated for a 25 cm2 area,
while imiquimod 3.75% is indicated for a treatment area no larger
than “full” face/scalp (29).
A limitation in this study is the small sample sizes for different
treatment strengths which required a pooled analysis. Another
limitation is that the real-world effectiveness was not evaluated by
a physician. However, patient-reported effectiveness was assessed
as a part of the TSQM questionnaire which can be used as a proxy
for clinical effectiveness in AK treatment (21).
It may be argued that the short treatment duration of ingenol
mebutate affects treatment adherence. A recent literature review
on adherence to topical AK therapies found that several studies
report that long and complex treatment regimens contribute to
decreased adherence (31–33). A UK survey of persons with AK
treated during the last 12months found nonadherence rates of
52% for treatment durations of 3–4weeks and of 72% for
6–12weeks of treatment. The results were supported by a web-
based survey of patient adherence and persistence of topical AK
therapies in Germany, France and the United Kingdom (42).
Treatment-induced HRQoL improvements were small and simi-
lar for all treatment groups in the present study. A previous US
study on treatment-induced changes in HRQoL among AK patients
and compared cryotherapy followed by topical treatment with
Figure 1. Treatment satisfaction in terms of treatment effectiveness, treatment convenience and global treatment satisfaction based on the TSQM-9 instrument.
Table 3. Patient-reported TSQM-9 score at follow-up, MMAS scores at follow-up,
AKQoL index at baseline and EQ-5D-5L & EQ-VAS at baseline as well as follow-
up and the difference there between.
Instrument Median Mean SD Min Max p value
TSQM-9 effectiveness
Diclofenac 50.0 52.9 26.3 0 100 .022
Imiquimod 66.7 60.8 22.7 0 100
Ingenol mebutate 66.7 64.3 19.4 0 100
TSQM-9 convenience
Diclofenac 77.8 79.3 16.6 44 100 .537
Imiquimod 77.8 78.4 15.1 33 100
Ingenol mebutate 77.8 76.4 14.7 0 100
TSQM-9 global satisfaction
Diclofenac 57.1 60.8 23.1 0 100 .146
Imiquimod 64.3 64.2 21.0 0 100
Ingenol mebutate 57.1 59.6 21.6 0 100
MMAS
Diclofenac 0.0 0.7 0.9 0 3 <.001
Imiquimod 0.0 0.2 0.4 0 2
Ingenol mebutate 0.0 0.1 0.3 0 2
AKQoL
Diclofenac 7.0 7.2 4.5 0 21 .060
Imiquimod 5.0 5.6 4.4 0 23
Ingenol mebutate 5.0 5.4 4.2 0 19
EQ-5D-5L
Diclofenac
Baseline 0.946 0.919 0.130 0.347 1.000 .916
Follow-up 1.000 0.919 0.150 0.331 1.000
Difference 0.000 0.001 0.098 0.330 0.181
Imiquimod
Baseline 1.000 0.950 0.075 0.670 1.000
Follow-up 1.000 0.951 0.118 0.188 1.000
Difference 0.000 0.001 0.109 0.640 0.260
Ingenol Mebutate
Baseline 0.942 0.930 0.097 0.299 1.000
Follow-up 0.942 0.934 0.095 0.289 1.000
Difference 0.000 0.004 0.084 0.488 0.328
EQ-VAS
Diclofenac
Baseline 90.00 83.00 13.80 50.00 100.00 .266
Follow-up 80.00 81.00 14.50 45.00 100.00
Difference 0.00 2.00 12.30 40.00 30.00
Imiquimod
Baseline 85.00 84.50 11.70 40.00 100.00
Follow-up 90.00 85.10 13.30 20.00 100.00
Difference 0.00 0.60 11.10 55.00 25.00
Ingenol Mebutate
Baseline 85.00 82.80 13.40 35.00 100.00
Follow-up 85.00 83.20 13.80 30.00 100.00
Difference 0.00 0.50 9.91 40.00 30.00
SD: standard deviation.
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either ingenol mebutate or vehicle (43). The baseline EQ-5D and
EQ-VAS estimates of the present study were in line with those of
the US study, while the US study implied somewhat larger HRQoL
gains from treatment (0.033 with EQ-5D and 3.5 with EQ-VAS).
This may be due to the longer follow-up in the US study or the
inclusion of cryotherapy.
Our AKQoL estimates were in line with those of a recent
Danish study, whereas our EQ-5D-5L and EQ-VAS estimates were
somewhat higher (22). The authors of the Danish study argued
that the various HRQoL instruments are complementary in AK as
they measure different aspects of HRQoL (22). This is in line with
the reasoning in a literature review of the use of EQ-5D in eco-
nomic evaluations in dermatology, where the authors suggest
that although the EQ-5D is broad enough to allow comparison
between different diseases, it may not be specific enough to cap-
ture important aspects of HRQoL in dermatology (44). Therefore, it
is important to use both generic, dermatology- and disease spe-
cific HRQoL measures in dermatologic conditions such as AK (22).
In conclusion, topical AK treatment with ingenol mebutate
indicates greater treatment adherence compared to diclofenac
and imiquimod. Furthermore, patient reported (TSQM) effective-
ness were higher for patients with ingenol mebutate than diclofe-
nac. More research is needed about the association between
adherence and real-world effectiveness of AK treatments.
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